The annual American Society of Clinical Oncology (ASCO) meeting offered the best look yet at immuno-oncology (I/O) combinations seeking to dethrone Merck & Co.'s Keytruda (pembrolizumab) in front-line non-small-cell lung cancer. These included results from the CheckMate-9LA study that supported the recent approval of Bristol Myers Squibb's Opdivo (nivolumab) and Yervoy (ipilimumab) plus limited chemotherapy and Phase II findings for Roche's Tecentriq (atezolizumab) and anti-TIGIT mAb tiragolumab.
To provide FirstWord readers with rapid feedback on what the new readouts say about how Opdivo/Yervoy and Tecentriq/tiragolumab might impact the treatment landscape in NSCLC, we are hosting an expert call with a key opinion leader (KOL) later this week.
Key topics that will be discussed during the call include, among other things… what stands out about the risk/benefit profile for using Opdivo/Yervoy plus limited chemotherapy; how problematic is the regimen's adverse-event profile; do you have a sense of how much added benefit Yervoy brings to the table and will this impact your willingness to use the regimen; how often are you likely to prescribe this combination and are there particularly subgroups that might be early adopters; does it have the potential to really compete with Keytruda; initial thoughts on updated Phase II data for Tecentriq/tiragolumab; did Tecentriq's poor performance have any impact on your confidence in the results; what are the biggest unanswered questions about the regimen; and where could you see Tecentriq/tiragolumab fitting into the treatment algorithm?
Ask the expert!
Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving treatment landscape in front-line NSCLC.
We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.
As always, FirstWord would very much like to receive your feedback and suggestions.
To read more KOL Views articles, click here.